# Nuclide record olaparib (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/olaparib/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "olaparib" ;
  schema:name "Olaparib"@en ;
  schema:description "Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer."@en ;
  schema:url <https://nuclide.cc/drugs/olaparib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Olaparib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7083106> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olaparib> ;
  nuclide:status "approved" ;
  nuclide:modality "Small-molecule PARP inhibitor" ;
  schema:alternateName "Lynparza" ;
  nuclide:approval "US 2014: gBRCA ovarian cancer ≥3 lines", "US 2018: gBRCA HER2- metastatic breast cancer", "US 2022: Adjuvant gBRCA high-risk HER2- early breast cancer" ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:targets <https://nuclide.cc/targets/parp/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/>, <https://nuclide.cc/companies/merck/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06909825/> .